Related Experiment Video
Updated: May 16, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Hybrid APSO-Bayesian optimized triple-kernel SVR models for QSAR and rational design of
Runqian Tian1, Xiaoran Geng1, Mingyu Li1
1College of Computer Science and Technology, Qingdao University, Qingdao, Shandong, China.
Molecular Diversity
|May 14, 2026
Summary
This study developed predictive models for lysine-specific demethylase 1 (LSD1) inhibitors, identifying key molecular features for drug design against acute myeloid leukemia.
Area of Science:
- Medicinal Chemistry
- Computational Chemistry
- Pharmacology
Background:
- Lysine-specific demethylase 1 (LSD1) is a crucial therapeutic target for acute myeloid leukemia (AML).
- Developing novel small molecules to inhibit LSD1 activity is essential for AML treatment.
Purpose of the Study:
- To develop quantitative structure-activity relationship (QSAR) models for predicting the inhibitory activity of 1H-pyrrolo[2,3-c]pyridine derivatives against LSD1.
- To identify key molecular descriptors influencing LSD1 inhibition and guide the rational design of new drug candidates.
Main Methods:
- Development of five QSAR models using heuristic methods, XGBoost, and support vector regression (SVR).
- Construction of a triple-kernel SVR model optimized via Adaptive Particle Swarm Optimization and Bayesian strategies.
- Molecular docking and 100 ns molecular dynamics simulations to assess binding interactions and stability of lead compounds.
Main Results:
- The triple-kernel SVR model demonstrated excellent predictive performance ([Formula: see text], [Formula: see text]).
- Electronegativity of nitrogen atoms and hydrogen bond accepting capacity were identified as critical determinants for LSD1 inhibition.
- Molecular dynamics simulations confirmed the stability of the lead compound (46c) and its strong binding affinity ([Formula: see text] kcal/mol), driven by van der Waals forces and a key hydrogen bond with LEU183.
Conclusions:
- The developed QSAR models provide a valuable tool for designing potent LSD1 inhibitors.
- Compound 46c shows promising therapeutic potential for AML, warranting further investigation.
- Future research will focus on synthesizing and evaluating designed compounds in vitro for anticancer activity.
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:30Quantitative Aspects of Drug-Receptor Interaction
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower Kd...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).